TY - JOUR
T1 - Role of siRNA-based nanocarriers for the treatment of neurodegenerative diseases
AU - Mishra, Neeraj
AU - Ashique, Sumel
AU - Garg, Ashish
AU - Rai, Vineet Kumar
AU - Dua, Kamal
AU - Goyal, Amit
AU - Bhatt, Shvetank
N1 - Generated from Scopus record by KAUST IRTS on 2023-10-12
PY - 2022/5/1
Y1 - 2022/5/1
N2 - Neurodegenerative disorders (NDs) lead to the progressive degeneration of the structural and physiological functions of the central and peripheral nervous systems, resulting in lifelong cognitive and motor dysfunction. Although comprehensive treatment of NDs is lacking, small interfering (si)RNA has shown therapeutic utility in the form of cellular nuclease-driven downregulation of mRNA levels. Various nanotechnologies have been used to modulate crucial physicochemical and biopharmaceutical properties of siRNA to provide protection and to enhance biomembrane interactions, residence times, tissue absorption, and cellular internalization for improved cytoplasm and/or nucleus interactions. In this review, we highlight advances in, and the role of, siRNA-based nanocarriers for the treatment of various NDs.
AB - Neurodegenerative disorders (NDs) lead to the progressive degeneration of the structural and physiological functions of the central and peripheral nervous systems, resulting in lifelong cognitive and motor dysfunction. Although comprehensive treatment of NDs is lacking, small interfering (si)RNA has shown therapeutic utility in the form of cellular nuclease-driven downregulation of mRNA levels. Various nanotechnologies have been used to modulate crucial physicochemical and biopharmaceutical properties of siRNA to provide protection and to enhance biomembrane interactions, residence times, tissue absorption, and cellular internalization for improved cytoplasm and/or nucleus interactions. In this review, we highlight advances in, and the role of, siRNA-based nanocarriers for the treatment of various NDs.
UR - https://linkinghub.elsevier.com/retrieve/pii/S1359644622000034
UR - http://www.scopus.com/inward/record.url?scp=85123062573&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2022.01.003
DO - 10.1016/j.drudis.2022.01.003
M3 - Article
C2 - 35017085
SN - 1359-6446
VL - 27
SP - 1431
EP - 1440
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 5
ER -